Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CDA | P32320 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 3/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 6/20 | 0.40 |
| ▸ | UMPS | P11172 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790225 | 1.00 | HIF1A (0.43) | HIF1AMAPTCDAPYGLSLC5A2 | |
| SCHEMBL6790150 | 0.82 | HIF1A (0.43) | HIF1AMAPTCDAPYGLSLC5A2 | |
| SCHEMBL6785624 | 0.82 | HIF1A (0.43) | HIF1AMAPTCDAPYGLSLC5A2 | |
| SCHEMBL6790684 | 0.82 | SLC5A2 (0.50) | HIF1AMAPTCDAPYGLSLC5A2 | |
| SCHEMBL6784255 | 0.82 | SLC5A2 (0.50) | HIF1AMAPTCDAPYGLSLC5A2 | |
| SCHEMBL28708412 | 0.81 | UMPS (0.43) | HIF1AMAPTCDAPYGLSLC5A2 | |
| SCHEMBL22092162 | 0.81 | UMPS (0.43) | HIF1AMAPTCDAPYGLSLC5A2 | |
| SCHEMBL8973933 | 0.81 | UMPS (0.43) | HIF1AMAPTCDAPYGLSLC5A2 | |
| SCHEMBL4363380 | 0.80 | UMPS (0.51) | HIF1AMAPTCDAPYGLSLC5A2 | |
| SCHEMBL6789387 | 0.80 | UMPS (0.51) | HIF1AMAPTCDAPYGLSLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | PHARMASSET, INC. | 2004-12-30 | — | — | US | disclosed |
| CN-1527836-A | Antiviral agents for treatment of flaviviridae infections | — | 2004-09-08 | — | — | CN | disclosed |
| EP-1366055-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | Pharmasset Limited (BB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002048165-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | HAVCR2, MAVS, EIF2AK2 | HIF1A 3985/4885MAPT 2815/4885CDA 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.